GLG News by Users of Dermal Fillers (US)

WHAT ARE THE PROPER USES OF ANTIBIOTICS ON INFECTED SITES, "CLEAN SITES", POST-OP SITES, ETC.?AN ANALYSIS OF TODAY'S THINKING.FOR IMPETIGO IT WILL BE USED, IT WILL NOT REPLACE EXISTING MODALITIES, BUT WILL SUPPLEMENT, AND HAVE THE ADVANTAGE OF NOT BEING USED SYSTEMICALLY.ROBERT AUERBACH, MD

ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...

IT MAY LAST LONGER, PROBABLY MORE EXPENSIVE, INJECTION TECHNIQUE MAY BE MORE CRITICAL IF IT LAST LONGER, I.E. MORE VISCOUS LESS MALLEABLE.  HOW MUCH CLINICAL DATA IS AVAILABLE?HAVING USED FILLER MATERIAL FOR OVER 25 YEARS I HAVE EXPERIENCE WITH ALL OF THEM LONG-TERM.ROBERT AUERBACH, MD

 Altabax is a member of a new class of antibiotics and is a topical treatment for uncomplicated skin and skin structure infections due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. It's to be used twice daily use for a five-day period. Altabax’s unique...

Galderma has partnered with Anika to launch a hyaluronic acid product into the marketplace. It will be the first HA filler to be combined with Lidocaine.However, Medicis (with a 3 1/2 year headstart with Restylane) and Allergan's Juvederm will probably still take the lion's share of the filler market....

The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...

This and other studies are highly suggestive that Gadolinium agents used in radiographic studies are associated with NFD. A large scale study should be initiated to confirm this association, and for now these agents should be avoided in patients with renal disease.

I totally agree with this article. The conclusions from the FDA are incorrect, and the data appear to indicate that the TCI's are actually protective!!!! In any event it has created a false sense of a problem, where none exists, and decreases the use of these agents, which are safer than the existing...

This article is a good summary of the currently available techniques of excision, subcision, and resurfacing. It does not mention dermal grafting, a technique that I personally use quite often. The maximum correction that one can achieve is 50-70% with a combination of multiple techniques.

This product by Cytochroma is a vitamin D analog which is similar to Dovonex, a product that has been used for 13 years. Its efficacy is modest at best. This product may, repeat may be better, because it activates the vitamin D pathway, and inhibits catabolism of Vitamin D. Whether this makes the product...